Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been given an average recommendation of “Hold” by the ten analysts that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.2188.

A number of brokerages have weighed in on MRVI. Royal Bank Of Canada reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th.

Maravai LifeSciences Stock Performance

Maravai LifeSciences stock opened at $3.25 on Friday. The firm has a market capitalization of $829.92 million, a PE ratio of -3.87 and a beta of 0.34. The business’s 50-day simple moving average is $3.03 and its 200-day simple moving average is $2.58. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.49 and a current ratio of 5.29. Maravai LifeSciences has a 52 week low of $1.66 and a 52 week high of $6.21.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The business had revenue of $41.63 million for the quarter, compared to analyst estimates of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. Equities research analysts forecast that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Insider Activity at Maravai LifeSciences

In other news, CEO Bernd Brust acquired 93,358 shares of Maravai LifeSciences stock in a transaction on Wednesday, November 12th. The stock was bought at an average price of $3.21 per share, for a total transaction of $299,679.18. Following the transaction, the chief executive officer owned 250,559 shares of the company’s stock, valued at $804,294.39. The trade was a 59.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 2.11% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MRVI. The Manufacturers Life Insurance Company increased its stake in Maravai LifeSciences by 12.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after purchasing an additional 5,160 shares in the last quarter. Performa Ltd US LLC boosted its holdings in shares of Maravai LifeSciences by 33.3% in the second quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock valued at $55,000 after buying an additional 5,740 shares during the period. Ethic Inc. increased its position in shares of Maravai LifeSciences by 62.8% during the third quarter. Ethic Inc. now owns 16,951 shares of the company’s stock worth $49,000 after acquiring an additional 6,540 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Maravai LifeSciences by 121.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 18,021 shares of the company’s stock valued at $43,000 after acquiring an additional 9,870 shares in the last quarter. Finally, Sprott Inc. bought a new stake in Maravai LifeSciences in the 3rd quarter valued at $29,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.